Completed PHASE4 INTERVENTIONAL 2-arm NCT01675297

Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis

Sponsor: Hanlim Pharm. Co., Ltd.

Conditions Osteoporosis

Interventions Risedronate Risedronate/Cholecalciferol combination

Updated 10 times since 2017 Last updated: Jun 23, 2019 Started: Jul 4, 2011 Primary completion: Dec 31, 2013 Completion: Apr 15, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Osteoporosis, this trial is completed. The trial is conducted by Hanlim Pharm. Co., Ltd. and has accumulated 10 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4

▶ Show 5 earlier versions

Dec 2021 — Dec 2022 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4
Sep 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jun 2018 — Sep 2019 [monthly]

Unknown Status PHASE4
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hanlim Pharm. Co., Ltd.

Data source: Hanlim Pharm. Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea